Cellectis
CLLS
42 hedge funds and large institutions have $167M invested in Cellectis in 2017 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 10 closing their positions.
49% more call options, than puts
Call options by funds: $2.45M | Put options by funds: $1.64M
23% more capital invested
Capital invested by funds: $136M → $167M (+$31.3M)
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
2% more funds holding
Funds holding: 41 → 42 (+1)
1.72% more ownership
Funds ownership: 14.86% → 16.58% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$9.96M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.75M |
| 3 |
Morgan Stanley
New York
|
+$2.6M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$2.07M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.97M |
| 2 |
O
OrbiMed
New York
|
-$1.73M |
| 3 |
Lazard Asset Management
New York
|
-$1.36M |
| 4 |
Millennium Management
New York
|
-$916K |
| 5 |
GH
GAM Holding
Zurich,
Switzerland
|
-$870K |
CLLS Hedge Fund Activity: Q3 2017 in Review
42 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Cellectis (CLLS) for Q3 2017, worth a combined $167M — up 23% from $136M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new CLLS positions and 10 closed out — a net gain of 1 holder — while 11 added to existing stakes and 9 trimmed.
The largest buyer was Farallon Capital Management, opening a new position worth an estimated $9.96M. The largest seller was DAFNA Capital Management, exiting entirely with an estimated $1.97M sold.
- 42 institutional investors held Cellectis (CLLS) as of Q3 2017, up from 41 in Q2 2017.
- Funds reported $167M of Cellectis stock for Q3 2017, up 23% quarter-over-quarter.
- 11 funds opened new Cellectis positions in Q3 2017 and 10 closed out, a net change of +1 holder.
- The largest Cellectis buyer in Q3 2017 was Farallon Capital Management, an estimated $9.96M added.
- The largest Cellectis seller in Q3 2017 was DAFNA Capital Management, an estimated $1.97M sold.
Based on aggregated 13F filings for Q3 2017.